Results 181 to 190 of about 16,624 (211)

Favipiravir

Drugs of the Future, 2010
openaire   +1 more source

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Engineering, 2020
Qingxian Cai, Minghui Yang, Junxia Xia
exaly  

Favipiravir/levofloxacin

Reactions Weekly, 2022
openaire   +1 more source

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review

International Journal of General Medicine, 2021
Windi Fresha Qomara, Delya Nur Primanissa, Salma Hasni Amalia   +2 more
exaly  

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial

Clinical Infectious Diseases, 2022
Marisa Holubar, Aruna Subramanian, Natasha Purington   +2 more
exaly  

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

International Immunopharmacology, 2021
Masoud Solaymani-Dodaran, mostafa ghanei, Ensieh Vahedi   +2 more
exaly  

Mutagenesis in Norovirus in Response to Favipiravir Treatment

New England Journal of Medicine, 2018
Li-An Wong-Taylor, Richard A Goldstein, Judith Breuer   +2 more
exaly  

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

Antiviral Research, 2013
Brian B Gowen, Kimiyasu Shiraki, Donald F Smee   +2 more
exaly  

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

2020
Kimiyasu Shiraki
exaly  

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

EBioMedicine, 2020
Alex Salam, Joel Tarning, Qingyuan Zhan
exaly